Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Bupropion HCl MR 300mg in Healthy Adults
NCT05160090Phase 1Completed
- Sponsor
- Alembic Pharmaceuticals Ltd.
- Start
- Jan 2020
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bupropion in major depressive disorder (MDD) (2 arms), sponsored by Alembic Pharmaceuticals Ltd. Primary endpoints: Maximum Plasma Concentration at 96 hours, Area Under the Curve from time zero to last quantifiable concentration at 96 hours and 1 more. Started Jan 2020; status: completed.
02
Drugs
bupropion
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05160090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05160090.